1-17 of 17
Richard S Finn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

Subject Area:
Gastroenterology , Oncology
Yoon Jun Kim, Philippe Merle, Richard S. Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Ho Yeong Lim, Masafumi Ikeda, Alessandro Granito, Gianluca Masi, René Gerolami, Sung Bum Cho, Chih-Hung Hsu, Yi-Hsiang Huang, Long-Bin Jeng, Do Young Kim, Shi-Ming Lin, Matthias Pinter, Guoliang Shao, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Kung-Kai Kuo, Yilei Mao, Yih-Jyh Lin, Kangshun Zhu, Philip Twumasi-Ankrah, Javeed Khan, Maria Awan, Kirhan Ozgurdal, Shukui Qin
Journal: Liver Cancer
Liver Cancer 1–17.
https://doi.org/10.1159/000542285
Published Online: 18 December 2024
View article titled, Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Open the PDF for Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study in another window
Journal Articles

Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

Subject Area:
Gastroenterology , Oncology
Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Journal: Liver Cancer
Liver Cancer (2024) 13 (6): 655–668.
https://doi.org/10.1159/000539897
Published Online: 21 June 2024
View article titled, Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
Open the PDF for Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 in another window
Journal Articles

Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Subject Area:
Gastroenterology , Oncology
Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R. Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2024) 13 (5): 537–547.
https://doi.org/10.1159/000537947
Published Online: 26 February 2024
View article titled, Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
Open the PDF for Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT in another window
Journal Articles

Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study

Subject Area:
Gastroenterology , Oncology
Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Journal: Liver Cancer
Liver Cancer (2024) 13 (5): 548–560.
https://doi.org/10.1159/000537966
Published Online: 21 February 2024
View article titled, Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study
Open the PDF for Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study in another window
Journal Articles

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Tatsuya Yamashita, Hironori Koga, Ryosuke Take, Kyoko Yamada, Takashi Asakawa, Yuki Nakagawa, Masafumi Ikeda
Journal: Liver Cancer
Liver Cancer (2024) 13 (4): 401–412.
https://doi.org/10.1159/000535501
Published Online: 28 November 2023
View article titled, Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Open the PDF for Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study in another window
Journal Articles

A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet
Journal: Liver Cancer
Liver Cancer (2024) 13 (4): 451–457.
https://doi.org/10.1159/000535154
Published Online: 13 November 2023
View article titled, A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Open the PDF for A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116 in another window
Journal Articles

Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis

Subject Area:
Gastroenterology , Oncology
Arndt Vogel, Richard S. Finn, Marie-Hélène Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, Michael Leibfried, Catherine R. Mitchell, Sarah Batson, Gabrielle Redhead, Vincent E. Gaillard, Masatoshi Kudo
Journal: Liver Cancer
Liver Cancer (2023) 12 (6): 510–520.
https://doi.org/10.1159/000533166
Published Online: 29 July 2023
View article titled, Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis
Open the PDF for Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis in another window
Journal Articles

Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study

Subject Area:
High Impact Articles in Gastroenterology , Gastroenterology , Oncology
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Journal: Liver Cancer
Liver Cancer (2023) 12 (5): 479–493.
https://doi.org/10.1159/000529996
Published Online: 04 March 2023
View article titled, Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
Open the PDF for Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study in another window
Journal Articles

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab

Subject Area:
Gastroenterology , Oncology
Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng
Journal: Liver Cancer
Liver Cancer (2023) 12 (1): 44–56.
https://doi.org/10.1159/000525499
Published Online: 22 February 2023
View article titled, Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab
Open the PDF for Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab in another window
Journal Articles

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial

Subject Area:
Gastroenterology , Oncology
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Journal: Liver Cancer
Liver Cancer (2023) 12 (4): 309–320.
https://doi.org/10.1159/000529636
Published Online: 14 February 2023
View article titled, Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial
Open the PDF for Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial in another window
Journal Articles

IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Richard S. Finn, Peter R. Galle, Andrew X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni
Journal: Liver Cancer
Liver Cancer (2023) 12 (3): 238–250.
https://doi.org/10.1159/000528272
Published Online: 28 November 2022
View article titled, IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study
Open the PDF for IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study in another window
Journal Articles

Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)

Subject Area:
Gastroenterology , Oncology
Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun-Ming Rau, Masafumi Ikeda, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, David W. McIlwain, Reigetsu Yoshikawa, Kenichi Nakamura, Kun Liang, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu
Journal: Liver Cancer
Liver Cancer (2021) 10 (5): 451–460.
https://doi.org/10.1159/000516605
Published Online: 12 July 2021
View article titled, Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2)
Open the PDF for Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2) in another window
Journal Articles

Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma

Subject Area:
Gastroenterology , Oncology
Angel Alsina, Masatoshi Kudo, Arndt Vogel, Ann-Lii Cheng, Won Young Tak, Baek-Yeol Ryoo, Thomas R. Jeffry Evans, Carlos López López, Bruno Daniele, Soamnauth Misir, Min Ren, Namiki Izumi, Shukui Qin, Richard S. Finn
Journal: Liver Cancer
Liver Cancer (2020) 9 (1): 93–104.
https://doi.org/10.1159/000504624
Published Online: 16 December 2019
View article titled, Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
Open the PDF for Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma in another window
Journal Articles

Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection

Subject Area:
Gastroenterology , Oncology
Bingnan Zhang, Richard S. Finn
Journal: Liver Cancer
Liver Cancer (2016) 5 (3): 221–232.
https://doi.org/10.1159/000367763
Published Online: 10 May 2016
View article titled, Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection
Open the PDF for Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection in another window
Journal Articles

Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma

Subject Area:
Gastroenterology , Oncology
Abby B. Siegel, Anthony B. El-Khoueiry, Richard S. Finn, Katherine A. Guthrie, Abhishek Goyal, Alan P. Venook, Charles D. Blanke, Elizabeth C. Verna, Lorna Dove, Jean Emond, Tomoaki Kato, Benjamin Samstein, Ronald Busuttil, Helen Remotti, Amy Coffey, Robert S. Brown Jr
Journal: Liver Cancer
Liver Cancer (2015) 4 (2): 115–125.
https://doi.org/10.1159/000367734
Published Online: 08 April 2015
View article titled, Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma
Open the PDF for Phase I Trial of Sorafenib Following Liver Transplantation in Patients with High-Risk Hepatocellular Carcinoma in another window
Journal Articles

Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma

Subject Area:
Gastroenterology , Oncology
Jean-Luc Raoul, Joong-Won Park, Yoon-Koo Kang, Richard S Finn, Jun Suk Kim, Winnie Yeo, Blasé N Polite, Yee Chao, Ian Walters, Christine Baudelet, Riccardo Lencioni
Journal: Liver Cancer
Liver Cancer (2014) 3 (3-4): 439–450.
https://doi.org/10.1159/000343872
Published Online: 15 August 2014
View article titled, Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma
Open the PDF for Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma in another window
Journal Articles

Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition

Subject Area:
Gastroenterology , Oncology
Richard S. Finn
Journal: Liver Cancer
Liver Cancer (2012) 1 (3-4): 247–256.
https://doi.org/10.1159/000343839
Published Online: 29 November 2012
View article titled, Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition
Open the PDF for Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition in another window